CERE
Adage Capital Partners’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-609,765
| Closed | -$24.9M | – | 961 |
|
|
2024
Q2 | $24.9M | Buy |
609,765
+27,131
| +5% | +$1.11M | 0.05% | 382 |
|
|
2024
Q1 | $24.6M | Sell |
582,634
-36,572
| -6% | -$1.55M | 0.05% | 395 |
|
|
2023
Q4 | $26.3M | Sell |
619,206
-886,770
| -59% | -$37.6M | 0.05% | 347 |
|
|
2023
Q3 | $32.9M | Buy |
1,505,976
+755,976
| +101% | +$16.5M | 0.07% | 273 |
|
|
2023
Q2 | $23.8M | Buy |
750,000
+351,480
| +88% | +$11.2M | 0.05% | 359 |
|
|
2023
Q1 | $9.72M | Hold |
398,520
| – | – | 0.02% | 623 |
|
|
2022
Q4 | $12.6M | Hold |
398,520
| – | – | 0.03% | 573 |
|
|
2022
Q3 | $11.3M | Buy |
398,520
+78,520
| +25% | +$2.22M | 0.03% | 607 |
|
|
2022
Q2 | $8.46M | Sell |
320,000
-80,000
| -20% | -$2.12M | 0.02% | 710 |
|
|
2022
Q1 | $14M | Buy |
400,000
+90,000
| +29% | +$3.15M | 0.03% | 600 |
|
|
2021
Q4 | $10.1M | Buy |
310,000
+60,000
| +24% | +$1.95M | 0.02% | 692 |
|
|
2021
Q3 | $7.38M | Sell |
250,000
-250,000
| -50% | -$7.38M | 0.01% | 776 |
|
|
2021
Q2 | $12.8M | Sell |
500,000
-100,000
| -17% | -$2.56M | 0.03% | 625 |
|
|
2021
Q1 | $8.24M | Hold |
600,000
| – | – | 0.02% | 729 |
|
|
2020
Q4 | $9.95M | Buy |
600,000
+300,000
| +100% | +$4.97M | 0.02% | 593 |
|
|
2020
Q3 | $3.14M | Buy |
+300,000
| New | +$3.14M | 0.01% | 684 |
|